Press Releases
Read the latest news from Centauri
-
Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections
Read more: Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infectionsCentauri today announced that the Company’s lead clinical candidate in the ABX-01 programme, CTX-187, has received Qualified Infectious Disease Product (QIDP) designation from the US Food and Drug Administration (FDA).
-
Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate
Read more: Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidateCentauri today announced it has secured £6M from AMR Action Fund, extending the Company’s Series A round to £30M.
-
Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials
Read more: Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trialsCentauri announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M in funding for the development of their lead compound.
-
Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical Officer
Read more: Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical OfficerCentauri today announced the appointment of Dr. Debra Barker as Chief Medical Officer (CMO). Dr. Barker joins Centauri’s leadership team to advance therapeutic development pipelines.
-
Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections
Read more: Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infectionsCentauri today announced the publication of a peer-reviewed study in The Journal of Immunology. The paper presents proof-of-concept data for CTX-09, an early molecule built on the Company’s Alphamer® platform.
-
Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections
Read more: Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infectionsCentauri today announced the selection of its first clinical candidate in the ABX-01 programme. Based on the Company’s Alphamer® platform, the compound is designed to target serious Gram-negative bacterial infections in the lung.
-
Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives
Read more: Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectivesCentauri today announced it has been awarded a £1M grant by PACE (Pathways to Antimicrobial Clinical Efficacy), a pioneering initiative focused on early-stage antimicrobial drug and diagnostic discovery.
-
Centauri awarded follow-on CARB-X grant
Read more: Centauri awarded follow-on CARB-X grantCentauri has been awarded a grant of up to $2.7 million USD from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated addressing the rising threat of drug-resistant bacteria.
-
Centauri Therapeutics closes £24m Series A investment round
Read more: Centauri Therapeutics closes £24m Series A investment roundCentauri today announced the close of its £24 million GBP Series A investment round. The funds will support the continued advancement of the Company’s antimicrobial resistance (AMR) research and development.
